US FDA classification for Indore facility pending
Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.
CIPLA / Q1-FY24 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Albuterol recall and market share loss
Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.
Potential pricing pressure in US generics
While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.
Goa facility re-inspection uncertainty
Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.